Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
EAST RUTHERFORD, N.J., May 31, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference on June 7, 2017 at 2:30 p.m. EDT in New York City.
The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and a replay will be available for 90 days after the live event concludes.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura IR Associate Tel: +201 804 3037 Email: [email protected]
